- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
7
An Overview of Renal Physiology
Mitchell H. Rosner
Introduction
The kidney is responsible for varied and critical functions that maintain homeostasis (this can be seen in Table 7.1, which demonstrates the excretory capacity of the kidney). These functions include maintaining the volume and composition of the extracellular fluid (despite drastic and variable difference in daily intake), removal of toxic waste products (such as the end-products of metabolism such as urea, phosphates, sulfates, and uric acid), the conservation of essential nutrients (glucose, amino acids, electrolytes), regulation of acid–base balance, production of hormones (active 1,25-vitamin D and erythropoietin), regulation of blood pressure, and the excretion of drugs that are metabolized. In order to achieve these functions, the kidney acts as an integrative organ of its constitutive parts: the nephrons. There are approximately 1.2 million nephrons per kidney at birth and it is the function of these units that controls homeostasis.
The nephron consists of a series of specialized segments each with a specific function that impacts the final composition of the urine. Furthermore, hormonal influences affect the functions of these segments in order to control the final urine composition. Sequentially, the nephron includes the afferent and efferent arterioles which bring blood to and away (respectively) from the tubules, the glomerulus which is responsible for producing an ultrafiltrate of
blood that will enter the tubules through Bowman’s capsule, and then specialized tubular subsegments (the proximal tubule, loop of Henle, distal tubule, and cortical collecting duct). Within the tubule, each specialized portion consists of tubular cells with specific transport proteins that are responsible for the excretion and reabsorption of specific electrolytes and nutrients. For example, in the proximal tubule, specialized transport proteins are responsible for the reabsorption of glucose and amino acids and secretion of hydrogen ions (H+) (Fig. 7.1). Furthermore, specific disease processes, both genetically and acquired, target specific tubular subsegments and processes. The Fanconi syndrome, which can be either genetic or acquired (due to multiple myeloma or drugs such as ifosfamide), results from disruption of proximal tubular function. This leads to wasting of glucose, amino acid, and bicarbonate in the urine.
Glomerular Structure and
Function
The formation of urine begins with the filtration of plasma water and its nonprotein constituents for the glomerular capillaries into Bowman’s space(termedultrafiltration).Theforcesinvolved in glomerular ultrafiltration are the Starling forces(intravascularhydrostaticpressure,plasma oncotic pressure, hydrostatic pressure, and
C.R. Chapple and W.D. Steers (eds.), Practical Urology: Essential Principles and Practice, |
105 |
DOI: 10.1007/978-1-84882-034-0_7, © Springer-Verlag London Limited 2011 |
|
106 Practical Urology: EssEntial PrinciPlEs and PracticE
Table 7.1. daily renal turnover |
|
|
|
|
|
Filtered |
Excreted |
Reabsorbed |
Percentage of |
|
|
|
|
reabsorbed |
Water (l/day) |
180 |
1.5 |
178.5 |
99.2 |
na+(mmol/day) |
25,000 |
150 |
24,850 |
99.4 |
Hco − (mmol/day) |
4,500 |
2 |
4,498 |
99.9 + |
3 |
|
|
|
|
cl− (mmol/day) |
18,000 |
150 |
17,850 |
99.2 |
glucose (mmol/day) |
800 |
0.5 |
799.5 |
99.9 + |
calcium (mmol/day) |
540 |
10 |
530 |
98.1 |
Potassium (mmol/day) |
720 |
100 |
620 |
86.1 |
Urea (mmol/day) |
920 |
460 |
460 |
50 |
Note: a patient’s serum electrolytes remain remarkably constant despite wide variations in intake.
Na+ |
|
|
|
Glucose |
K+ |
3 Na+ |
|
Na+ |
ATP |
||
Na+ |
ADP |
||
|
|||
|
2 K+ |
ATP |
|
|
H+ |
ACTIVE- |
|
|
Energy |
||
|
|
||
|
|
dependent |
|
LUMINAL (urine) |
|
Basolateral (blood) |
Figure 7.1. schematic representation of transport processes occurring in the proximal tubule. sodium (na+) and glucose are absorbed from the luminal (urine) side of the proximal tubule through a specialized cotransporter. Hydrogen (H+) ions are excreted by a specific na+/H+anti-porter. the energy for these processes is derived from the basolateral (blood) side na+/ potassium (K+) atPase. this protein uses the energy from atP (adenosine tri-phosphate) breakdown to pump K+ into cells and na+ out of cells against their concentration gradients. in doing so, the intracellular K+ concentration is very high and the intracellular na+ concentration is very low. this allows na+ from the luminal side to flow down its concentration gradient into cells.in doing so, either cations (such as H+) can be secreted or other substances (glucose, amino acids) can be absorbed utilizing the movement of na+ down its concentration gradient.
oncotic pressure within Bowman’s space). The net result of the interplay of these forces is that there is net ultrafiltration into Bowman’s space from the capillary beds (termed glomerular filtration rate (GFR)). This filtrate is generally free of significant quantities of plasma proteins.
The glomerular capillary wall consists of three layers: (1) endothelial cells, (2) glomerular basement membrane, and (3) epithelial cells
(podocytes with foot processes). The endothelium is thought to be freely permeable to even large molecules but does exclude blood cells. The basement membrane consists of three filamentous layers (lamina rara interna, lamina densa, and lamina rara externa). Many consider the basement membrane to be the most important restrictive filtration barrier. The epithelium consists of highly specialized cells called podocytes that are attached to the basement membrane by foot processes (pedicels), which are separated by filtration slits bridged by thin diaphragms. These epithelial cells also have the ability to phagocytize macromolecules that have leaked through the basement membrane.Adding to the selective permeability characteristics of the glomerular filtration barrier is the presence of negatively charged glycosialoproteins, which tend to repel negatively charged plasma proteins such as albumin.
GFR is tightly regulated. Over a range of arterial pressures between 80 and 180 mmHg, total resistance varies in direct proportion to arterial pressure and the flow remains approximately unchanged. This phenomenon whereby renal blood flow (RBF) and glomerular filtration rate (GFT) are maintained constant is called autoregulation. Auto-regulation is achieved by changes within the kidney to affect renal blood flow and GFR. There are two factors which are responsible for autoregulation of renal blood flow and glomerular filtration rate, (1) myogenic mechanism, this is a pressure sensitive mechanism in which there is an intrinsic tendency of vascular smooth muscle to contract when it is
107
an ovErviEW of rEnal PHysiology
stretched. As arterial pressure increases, the |
a creatinine clearance tends to overestimate the |
afferent arteriole is stretched and the smooth |
true GFR by the amount that is secreted into the |
muscle contracts, (2) tubuloglomerular feedback: |
urine. |
this mechanism involves a feedback loop in which |
Given that creatinine clearance is only an esti- |
the macula densa of the distal tubule cells senses |
mate of GFR and in some cases creatinine secre- |
some component of the distal tubule fluid (likely |
tion by the tubules can be increased (such as |
chloride concentration), which then affects GFR. |
with chronic kidney disease), there is a need for |
For example, when GFR increases, distal tubule |
a more precise and more easily obtained mea- |
flow rate increases sending a signal that causes |
sure of GFR. Furthermore, collection of 24 h |
RBF and GFR to return to normal levels. Other |
urine is difficult and unreliable. Using data from |
factors that alter renal blood flow and GFR |
thousands of patients in the Modification of |
include, (1) sympathetic control: sympathetic |
Diet in Renal Disease (MDRD) trial where sensi- |
neurons that release norepinephrine innervate |
tive GFR was measured, a regression equation |
both the afferent and efferent arterioles. |
was developed that allows a serum creatinine |
Norepinephrine produces vasoconstriction by |
value to be converted into an estimated GFR |
binding to alpha 1-adrenoceptors, thereby |
with a high degree of correlation to a measured |
decreasing renal blood flow and glomerular fil- |
GFR. The equation requires only a measure- |
tration rate; (2) hormones: there are various |
ment of serum creatinine: GFR = 175 × serum |
vasoconstrictor hormones including epineph- |
creatinine – 1.154 × age – 0.203 × 1.212 [if black] |
rine, norepinephrine, angiotensin II, thrombox- |
× 0.742 [if female]. Use of this equation has |
ane, and parathyroid hormone. Vasodilator hor- |
gained widespread acceptance as a method for |
mones include PGE2, PGI2, bradykinin, hista- |
determining and following GFR. |
mine, and atrial natriuretic peptide; (3) protein |
|
intake: high protein intake increases both GFR |
Body Fluid Compartments |
and renal blood flow. |
|
The GFR is equal to the sum of the filtration |
|
rates of all the functioning nephrons and thus is |
The amount of the body that is composed of |
an important index of kidney function and it is |
water is variable and dependent upon the |
used clinically as a global marker of kidney |
amount of fat. Thus, patients with higher body |
function. A decreasing GFR is a sensitive and |
fat percentages will have lower water content. |
vitally important marker of worsening kidney |
For this reason, women tend to have about 5% |
function. While there are many methods for |
less total body water than men. Total body water |
determining the GFR, two are used most com- |
constitutes approximately 60% of body weight |
monly in the clinical setting: (1) creatinine clear- |
(or 42 L for a 70 kg male). This is further divided |
ance determination from a 24-h urine collection |
into an intracellular compartment (40% of body |
or (2) use of regression formulas to determine |
weight) and an extracellular compartment (20% |
GFR based upon serum creatinine measure- |
of body weight). The extracellular compartment |
ments. Creatinine clearance is determined by |
is further divided into an intravascular (5% of |
the collection of a 24-h urine specimen and a |
body weight) and interstitial compartments |
plasma sample, both of which are measured for |
(15% of body weight). |
creatinine concentration. Given that, in the |
The major solute constituents are electrolytes |
steady state, creatinine excretion is equal to the |
with a smaller proportion of proteins, nutrients, |
creatinine filtration rate, clearance can be deter- |
and waste products. Sodium is by far the most |
mined as the urine concentration of creatinine |
abundant extracellular cation, while chloride |
multiplied by the urine volume divided by the |
and bicarbonate are the most abundant extra- |
plasma concentration of creatinine. In should be |
cellular anions. Potassium is the most abundant |
noted that this relationship holds true only for |
intracellular cation and organic phosphates and |
an ideal molecule that only appears in the urine |
proteins are the most abundant intracellular |
via glomerular filtration and then is not secreted, |
anions. In order to maintain the unequal distri- |
metabolized, or absorbed by the tubules. While |
bution of solutes across body compartments, |
creatinine is freely filtered and does not undergo |
several mechanisms are operative: (1) semiper- |
either tubular reabsorption, it can undergo |
meable cell membranes, and (2) the existence of |
tubular secretion. Thus, a GFR calculated using |
cellular channels and pumps (transporters) that |
|
|
|
108 |
|
|
|
|
|
|
|
|
|
Practical Urology: EssEntial PrinciPlEs and PracticE |
|
use energy to maintain a difference in solute |
proximal sodium reabsorption also decreases |
|||
concentrations across the membranes. |
|
by 25%. Thus the net effect of GT-balance is to |
||
The osmolality of interstitial fluid is equal to |
minimize the ability of changes in GFR to pro- |
|||
that of intracellular fluid, and changes in osmo- |
duce large changes in sodium excretion. |
|||
lality between these compartments govern fluid |
|
|||
movement. For instance, if the osmolality of the |
|
|||
extracellularcompartmentwasacutelyincreased |
Control of Body Osmolality and |
|||
(for instance, with mannitol) this would cause |
||||
Body Fluid Volume |
||||
water movement out of cells down the osmotic |
||||
gradient into the extracellular compartment. |
|
|||
The volume of the extracellular compartment |
The osmolality of the extracellular fluid (ECF) is |
|||
is dependent upon the amount of body sodium |
tightly regulated with variations of only 1–2% in |
|||
(since this is the major extracellular cation). |
normal circumstances. This need for tight con- |
|||
Within the extracellular compartment, hydro- |
trol is due to the important effect of osmolality |
|||
static and oncotic pressures (Starling forces) |
on cellular volume. For example, if the osmolal- |
|||
determine the movement of fluid and volume |
ity of the ECF falls, it creates a disequilibrium |
|||
between the plasma and interstitial spaces. |
favoring movement of water into the intracellu- |
|||
|
|
|
lar compartment with resultant cellular swell- |
|
Regulation of Sodium, Chloride, |
ing. In the central nervous system, this can lead |
|||
to intracranial hypertension and mental status |
||||
and Water Reabsorption by the |
changes that in the extreme can lead to cerebel- |
|||
|
|
|
||
Proximal Tubule |
|
lar herniation and death. This contrasts with the |
||
|
volume of the ECF fluid, which is not as tightly |
|||
|
|
|
regulated and can vary by a much larger per- |
|
Important factors regulating the movement of |
centage. Body osmolality is regulated by renal |
|||
solute and water from proximal tubule lumen |
handling of water and is under the control of |
|||
into the peritubular capillaries are the Starling |
arginine vasopressin (AVP, or antidiuretic hor- |
|||
forces which include capillary oncotic pressure |
mone (ADH)). Body volume is regulated by |
|||
(pcap), the hydrostatic pressure in the intercellu- |
renal handling of sodium and the major media- |
|||
lar space (Pis), the interstitial oncotic pressure |
tors are the renin-angiotensin-aldosterone sys- |
|||
(pis), and the capillary hydrostatic |
pressure |
tem (RAAS) and the sympathetic nervous |
||
(Pcap). Peritubular capillary pressure can be |
system (SNS). |
|||
altered by the vascular tone of the efferent arte- |
In response to water deprivation (or sodium |
|||
riole. An increase in efferent arteriole tone will |
ingestion), plasma osmolality is increased. This |
|||
reduce peritubular capillary pressure (provid- |
is sensed by osmoreceptors in the supraoptic |
|||
ing less hindrance to solute reabsorption). On |
and paraventricular nuclei in the hypothalamus |
|||
the other hand, a decrease in efferent arteriole |
and leads to the release of AVP. AVP is released |
|||
tone will increase peritubular capillary pressure |
in response to either increased osmolality (less |
|||
and increase hindrance to solute reabsorption. |
than 1% change) or decreased volume (greater |
|||
Furthermore, the peritubular oncotic pressure |
than 10% change) of the ECF. Note that secre- |
|||
can be altered by the efferent arteriole as well. |
tion of AVP in response to increased osmolality |
|||
Efferent arteriole constriction can increase |
has a lower threshold and a higher sensitivity |
|||
the filtration fraction (FF = GFR/RPF), which |
(slope) than the response to decreased ECF vol- |
|||
will increase peritubular oncotic |
pressure. |
ume. The hypothalamic receptors also increase |
||
An increase in peritubular oncotic pressure |
thirst. AVP then acts to increase the water per- |
|||
will increase solute and water reabsorption by |
meability of the collecting duct in the distal |
|||
the proximal tubule. These forces are involved |
tubuleresultinginfreewaterretention,decreased |
|||
in a phenomenon known as glomerulotubular |
urine volume, and increased urine osmolality. |
|||
balance (G-T balance). The operation of G-T |
The combination of thirst and increased free |
|||
balance enables a constant fraction of filtered |
water reabsorption by the kidney restores |
|||
sodium and water to be reabsorbed by the prox- |
plasma osmolality to normal. |
|||
imal tubule despite variations in GFR. For exam- |
In contrast, in the setting of excess water |
|||
ple, when GFR decreases by 25% the rate of |
ingestion, plasma osmolality is decreased and |